The story of the erectile dysfunction drug presents a complex picture for shareholders. While the initial release generated significant gains, the end of its patent opened the floodgates to off-brand alternatives, https://bookmarkingdepot.com/story21568202/the-copyright-and-big-pharma-a-volatile-bet